Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

You may want to tell him human trials for diabetic foot ulcers haven't been set up yet. And, even if they were, there is no way to know that Boston would be the location. Promising research has been done that will likely lead to clinical trials, but, don't get his hopes up for anything coming soon. The company has their hands full with the current ongoing and soon to be started trials.

Following is from last corporate update on April 21, 2015:

http://cellceutix.com/cellceutix-provides-corporate-update/#sthash.OKWaNHb8.dpbs

Other

Elsewhere in our extensive pipeline, we and/or our partners have conducted very promising research that supports additional clinical trials that we plan to focus on in the future. Namely, we are developing formulations for ophthalmic, otic and diabetic foot infections. We have a growing body of evidence to the potential efficacy of our HDP mimetic compounds for the treatment of Gram-negative bacteria and fungal pathogens. In light of the awareness and government initiatives to develop new drugs to stop so-called “superbugs” that are resistant to most or all of today’s therapies, compounds addressing multi-drug resistant bacterial and fungal diseases and conditions are extremely valuable and of high profile today. We have disclosed that research, much of which is conducted under government grants at a major university in Texas and by Fox Chase Chemical Diversity Center. These studies show that our HDP mimetics are active with low toxicity against some of today’s most problematic pathogens, such as Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli and Acinetobacter baumannii, as well as highly multi-drug resistant ndm-1-producing Klebsiella pneumoniae. Lab research on CTIX-1502, one of our early lead compounds, has shown it to be active against systemic and localized Candida infections, including being comparable or superior to the commonly used topical anti-fungal agent nystatin in an oral candidiasis mouse model. With respect to these different indications, we are manufacturing compounds as GMP material and intend to move forward to initiate a broad Phase 1 trial to define which indications are best targeted.

In Reply to 'Echo20'
The Dane

Absolutly real and true.

He wants to be in the Bricilidin trials in Boston.

The picture has been trouble but the situation is very real.

ECHO20